Under construction – not a live service
Sign in
Enrolling by invitationPhase 3

Open-label extension study of vormatrigine in adults with epilepsy

Continues vormatrigine treatment in adults aged 18 to 85 with epilepsy.

Plain-language title generated from the registry record
Registry title: Clinical Trial of Vormatrigine in Adult Patients With Epilepsy

Key facts

Where
Porto Alegre and São José do Rio Preto, BrazilSee the 2 sites
Phase
Phase 3

AI summary: who the study is looking for

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with epilepsy who finished an earlier vormatrigine trial or already received vormatrigine outside a trial, such as in an expanded access program.

Age
18 to 85 years
Sex
Men and women can join.
Disease stage
Epilepsy with tonic-clonic, focal or primary generalized seizures.
Earlier treatment
Must have finished an earlier vormatrigine trial (for example PRAX-628-212 or PRAX-628-321) or have received vormatrigine outside a trial.

Main reasons for not taking part

  • Stopped or left the treatment period of an earlier vormatrigine trial early (unless the sponsor agrees)
  • Plans to join another investigational study or takes a prohibited medication
  • Is pregnant, breastfeeding or plans to become pregnant
  • The investigator judges the person cannot join the extension trial

Read by machine on 9 November 2026.

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 85 years old?

Source: NCT07287163, who can take part

Where in Brazil

  • Porto AlegreHospital not named in the registryNo longer taking part
  • São José do Rio Preto, São PauloHospital not named in the registryNo longer taking part

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Trial details

Who runs it
Praxis Precision Medicines
Trial code
NCT07287163
Record updated
3 August 2026
Original description
Open Label Extension Clinical Trial of Vormatrigine in Adult Patients with EpilepsyRead full original descriptionShow less

Open Label Extension Clinical Trial of Vormatrigine in Adult Patients With Epilepsy

Open Label Extension Clinical Trial of Vormatrigine in Adult Patients with Epilepsy

Inclusion: Participant who completed an eligible clinical trial (unless agreed by the sponsor medical monitor), including PRAX-628-212, PRAX-628-321 or other vormatrigine trials, or participant who has received vormatrigine outside of an eligible clinical trial (such as an expanded access program); Participant who had adequate seizure diary and vormatrigine adherence and had been otherwise adherent to the study procedures in the opinion of the investigator unless deemed unacceptable by sponsor.

Exclusion: Participant who plans to enter another interventional investigational study or is on any prohibited medication; Participant who withdrew or discontinued treatment from the treatment period of an eligible clinical trial unless deemed acceptable by the sponsor; Participant who is pregnant, lactating or planning to become pregnant; Participant who is ineligible for the extension clinical trial in the view of the investigator.

ClinicalTrials.gov NCT07287163